Hong Kong has introduced more measures to incentivize companies to submit their drug marketing applications using the “1+” mechanism it launched last November to speed up the registration of products containing new chemical or biological entities for life-threatening or severely-debilitating diseases.
In addition, the country has implemented a new refuse-to-file (RTF) mechanism to “enhance its timeliness and efficiency” in managing the review of applications for the initial
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?